

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number  
**WO 2005/044848 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 14/47**

(74) Agent: JANG, Seongku; 19th Fl., KEC Building, #275-7,  
Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).

(21) International Application Number:  
PCT/KR2004/002888

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
9 November 2004 (09.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10-2003-0079482  
11 November 2003 (11.11.2003) KR

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**NATIONAL CANCER CENTER [KR/KR]**; 809,  
Madu-1-dong, Ilsan-gu, Goyang-si, Kyungki-do 411-351  
(KR).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **CHUNG, Junho**  
[KR/KR]; 501, #98-2, Changseong-dong, Jongro-gu,  
Seoul 110-034 (KR). **HUR, Youngmi** [KR/KR]; B02,  
#683-34, Hannam-2-dong, Yongsan-gu, Seoul 140-212  
(KR).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NEUTRALIZABLE EPITOPE OF HGF AND NEUTRALIZING ANTIBODY BINDING TO THE SAME



(57) Abstract: The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met.